SCIENTIFIC publications

/cun/en/investigacion/publicaciones-cientificas/areaMain/02
  • Efficacy of bortezomib to intensify the conditioning regimen and the graft-versus-host disease prophylaxis for high-risk myeloma patients undergoing transplantation

    Caballero-Velázquez T (1), Calderón-Cabrera C (1), López-Corral L (2), Puig N (2), Marquez-Malaver F (1), Pérez-López E (2), García-Calderón C (1), Rosso-Fernández CM (1), Caballero Barrigón D (2), Martín J (1), Mateos MV (2), San Miguel J (3), Pérez-Simón JA (4); European Myeloma Network.

    (1) Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), Universidad de Sevilla, Seville, Spain.
    (2) Department of Hematology, Complejo Asistencial Universitario de Salamanca-IBSAL-CIBERONC, Centro de Investigación del Cáncer-IBMCC, Salamanca, Spain.
    (3) Clínica Universidad de Navarra, Centro Investigación Médica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona, Spain.
    (4) Department of Hematology, University Hospital Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC/CIBERONC), Universidad de Sevilla, Seville, Spain.

    Bone Marrow Transplantation 24 SEPTEMBER 2019

  • Electrical Vestibular Stimulation in Humans: A Narrative Review

    Sluydts M (1), Curthoys I (2), Vanspauwen R (3), Papsin BC (4), Cushing SL (4), Ramos A (5), Ramos de Miguel A (5), Borkoski Barreiro S (5), Barbara M (6), Manrique M (7), Zarowski A (3).

    (1) European Institute for Otorhinolaryngology, GZA Hospitals Antwerp, Wilrijk, Belgium, morgana.sluydts@gza.be.
    (2) Vestibular Research Laboratory, University of Sydney, Sydney, New South Wales, Australia.
    (3) European Institute for Otorhinolaryngology, GZA Hospitals Antwerp, Wilrijk, Belgium.
    (4) Department of Otolaryngology - Head and Neck Surgery, The Hospital for Sick Children, Toronto, Ontario, Canada.
    (5) Hearing Loss Unit, Otorhinolaryngology, Head and Neck Department, Complejo Hospitalario Universitario Insular Materno Infantil, Las Palmas of Gran Canaria, Spain.
    (6) NESMOS Department, ENT Clinic, Sapienza University, Roma, Italy.
    (7) Otorhinolaryngology Department, Clinica Universidad de Navarra, Pamplona, Spain.

    Audiology & Neuro-otology 18 SEPTEMBER 2019

  • EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks

    Gouya L (1), Ventura P (2), Balwani M (3), Bissell DM (4), Rees DC (5), Stölzel U (6), Phillips JD (7), Kauppinen R (8), Langendonk JG (9), Desnick RJ (3), Deybach JC (1), Bonkovsky HL (10), Parker C (7), Naik H (3), Badminton M (11), Stein PE (5), Minder E (12), Windyga J (13), Bruha R (14), Cappellini MD (15), Sardh E (16), Harper P (16), Sandberg S (17), Aarsand AK (17), Andersen J (17), Alegre F (18), Ivanova A (19), Talbi N (20), Chan A (21), Querbes W (21), Ko J (21), Penz C (21), Liu S (21), Lin T (21), Simon A (21), Anderson KE (22).

    (1) Centre de Référence Maladies Rares Porphyries, Colombes, France.
    (2) Università degli Studi di Modena e Reggio Emilia, Emilia-Romagna, Italy.
    (3) Icahn School of Medicine at Mount Sinai, New York, NY, USA.
    (4) University of California, San Francisco, CA, USA.
    (5) King's College Hospital, King's College London, London, UK.
    (6) Klinikum Chemnitz Porphyria Center, Chemnitz, Germany.
    (7) University of Utah, Salt Lake City, UT, USA.
    (8) University Hospital of Helsinki, Helsinki, Finland.
    (9) Porphyria Center, Center for Lysosomal and Metabolic Disease, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, The Netherlands.
    (10) Section on Gastroenterology & Hepatology, Wake Forest University/NC Baptist Medical Center, Winston-Salem, NC, USA.
    (11) University Hospital of Wales, Cardiff, UK.
    (12) Stadtspital Triemli, Zentrallabor, Zurich, Switzerland.
    (13) Department of Hemostatic Disorders and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
    (14) 4th internal clinic, General University Hospital, Charles University, Prague, Czech republic.
    (15) University of Milan, Fondazione IRCCS, Ca Granda, Milan, Italy.
    (16) Porphyria Centre Sweden, Centre for Inherited Metabolic Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
    (17) Norwegian Porphyria Centre, Haukeland University Hospital, Bergen, Norway.
    (18) Clinica Universidad de Navarra, Navarra, Spain.
    (19) St. Ivan Rilski U Hospital, Sofia, Bulgaria.
    (20) Laboratory of Excellence GR-Ex, University of Paris, Paris, France.
    (21) Alnylam Pharmaceuticals, Cambridge, MA, USA.
    (22) University of Texas Medical Branch, Galveston, TX, USA

    Hepatology 12 SEPTEMBER 2019

  • Emphysema phenotypes and lung cancer risk

    González J (1), Henschke CI (2), Yankelevitz DF (2), Seijo LM (1), Reeves AP (3,4), Yip R (2), Xie Y (3), Chung M (2), Sánchez-Salcedo P (5), Alcaide AB (1), Campo A (1), Bertó J (1), Del Mar Ocón M (1), Pueyo J (6), Bastarrika G (6), de-Torres JP (1,7), Zulueta JJ (1,7,8,9).

    (1) Pulmonary Service, Clínica Universidad de Navarra, Pamplona, Spain.
    (2) Department of Radiology Mount Sinai School of Medicine, NY, United States of America.
    (3) School of Electrical and Computer Engineering, Cornell University, Ithaca, NY, United States of America.
    (4) Vision, Inc, Ithaca, NY, United States of America.
    (5) Pulmonary Service, Complejo Hospitalario de Navarra, Pamplona, Spain.
    (6) Radiology Department, Clínica Universidad de Navarra, Pamplona, Spain.
    (7) Navarra's Health Research Institute (IDISNA), Pamplona, Spain.
    (8) CIBERONC, ISCIII, Madrid, Spain.
    (9) VisionGate, Inc, Phoenix, Arizona, United States of America.

    PLoS One 25 JULY 2019

  • Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation

    Idoate Grijalba AI (1), Aldaz Pastor A (2), Marquet P (3,4,5), Woillard JB (3,4,5).

    (1) Pharmacy department, Clinica Universidad de Navarra, 31008, Pamplona, Spain.
    (2) Pharmacy department, Clinica Universidad de Navarra, 31008, Pamplona, Spain.
    (3) IPPRITT, Univ. Limoges, F-87000, Limoges, France.
    (4) IPPRITT, INSERM, U1248, F-87000, Limoges, France.
    (5) CHU Limoges, F-87000, Limoges, France.

    European Journal of Clinical Pharmacology 23 JULY 2019

you mayBE INTERESTED

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra